News | January 07, 2015

Minneapolis Heart Institute Among First in U.S. to Implant Lotus Heart Valve

The Lotus consists of a pre-loaded, stent-mounted tissue valve prosthesis and catheter delivery system for guidance and percutaneous placement of the valve

January 7, 2015 — Minneapolis Heart Institute Foundation (MHIF) researchers have performed two implants of the Lotus Cardiac Valve System as part of the REPRISE III clinical trial. With these procedures, Minneapolis Heart Institute at Abbott Northwestern Hospital has become the third facility in the United States to perform Lotus valve implants, and the first west of the Mississippi.

The patients, who were the seventh and eighth to receive Lotus valve implants in the United States, are both 85-year-old women who suffered from advanced aortic valve stenosis and were deemed high-risk and ineligible for traditional valve replacements through open heart surgery.

Both patients underwent transcatheter aortic valve replacement (TAVR) procedures on Tuesday, November 11. They are both scheduled to return to Minneapolis Heart Institute at Abbott Northwestern to assess their progress and to determine whether their TAVR procedures were successful.

Clinical research into TAVR devices such as the Lotus Cardiac Valve System is important because it provides options to an underserved population – older patients that are generally considered too high-risk for open-heart surgery.

Wesley R. Pedersen, M.D., director of Transcatheter Valve Therapies for the Minneapolis Heart Institute at Abbott Northwestern Hospital is the principal investigator for this study. He states, “The ability of this valve to be fully repositioned offers an advantage over existing technology. If initial placement results in suboptimal function, it can be recaptured and moved to a slightly different position where valve function is most ideal.” In the United States the Lotus Valve System is an investigational device and not available for sale. It is CE marked in the European Union.

For more information: www.mplsheart.org

 

Related Content

Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-femor
The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.  #SCAI, #SCAI2018

The use of 3-D printed hearts from patients' pre-TAVR planning CT scans have improved outcomes of procedures at the University of Minnesota. Clearly identifying where calcium is located on the valves prior to TAVR device implantation has helped reduce the incidence of paravalvular leak.

News | Heart Valve Technology | May 14, 2018
May 14, 2018 – A new study examines the effectiveness of 3-D printing technology and computer modeling to predict par
First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing...
Medtronic Shares Two-Year Harmony Transcatheter Pulmonary Valve Results at SCAI 2018. #SCAI, #SCAI2018
News | Heart Valve Technology | May 11, 2018
Medtronic plc announced two-year outcomes for the Harmony Transcatheter Pulmonary Valve (TPV) from its early...
Colibri Heart Valve Continues Enrollment in TAVI Early Feasibility Study
News | Heart Valve Technology | May 07, 2018
Colibri Heart Valve LLC announced the Colibri transcatheter aortic valve implantation (TAVI) System has been used on an...
An 3D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

A 3-D echo view of a Neovasc Tiara transcatheter mitral valve. This valve is currently in clinical trials and is ahead of most of the TMVR devices in development.

Feature | Heart Valve Technology | May 04, 2018 | Dave Fornell, Editor
May 4, 2018 — Transcatheter val...
Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy - Cardioband Tricuspid Valve Reconstruction System
News | Heart Valve Technology | May 01, 2018
Edwards Lifesciences Corp.announced that it received CE Mark for the Edwards Cardioband Tricuspid Valve Reconstruction...
Overlay Init